FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

Month of October 2011

Commission File Number — 1-15182

DR. REDDY’S LABORATORIES LIMITED

(Name of Registrant)

8-2-337, Road No. 3, Banjara Hills
Hyderabad, Andhra Pradesh 500 034, India
+91-40-4900-2900

(Address of Principal Executive Offices)

Indicate by check mark whether registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F þ      Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o       No þ

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b):

Not applicable.

 

 

Table of Contents

(1) Press Release, “Dr. Reddy’s Q2 FY12 Financial Results,” October 25, 2011.			3
(2) Press Release, “Teva and Dr. Reddy’s announce launch of generic Zyprexa® in the United States,” October 25, 2011.			9

Press Release
		Dr. Reddy’s Laboratories Ltd.
		8-2-337, Road No. 3
		Banjara Hills, Hyderabad — 500 034
		Andhra Pradesh, India
		Tel: 91-40-4900-2900
		Fax: 91-40-4900-2999
		www.drreddys.com

Dr. Reddy’s Q2 FY12 Financial Results

Q2 FY12 Revenues at 22.7 billion ($462 million), YoY growth of 21%

Q2 FY12 Adjusted* EBITDA at 5.1 billion ($104 million), YoY growth of 20%

Q2 FY12 Adjusted** PAT at 3.1 billion ($63 million), YoY growth of 8%

Hyderabad, India, October 25, 2011: Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) today announced its unaudited consolidated financial results for the quarter ended September 30, 2011 under International Financial Reporting Standards (IFRS).

Key Highlights

•

Consolidated revenues are at 22.7 billion ($462 million) in Q2 FY12 versus 18.7 billion ($381 million) in Q2 FY11, year-on-year growth of 21%. Consolidated revenues for H1 FY12 is at 42.5 billion ($866 million).

•

Revenues from Global Generics for Q2 FY12 are at 16.1 billion ($329 million). Year-on-year growth of 18% mainly driven by North America and Russia.

•

Revenues from PSAI are at 5.9 billion ($121 million) in Q2 FY12, growth of 28% over previous year.

•

Adjusted* EBITDA of 5.1 billion ($104 million) in Q2 FY12, is at 23% of revenues recording year-on-year growth of 20%. Consolidated adjusted EBITDA for H1 FY12 is at 9.4 billion ($193 million).

•

Adjusted**Profit after Tax for Q2 FY12 is at 3.1 billion ($63 million), is at 14% of revenues with year-on-year growth of 8%. Consolidated adjusted PAT for H1 FY12 is at 5.6 billion ($115 million).

•

During the quarter, the company launched 28 new generic products, filed 17 new product registrations and filed 11 DMFs globally.

•

Dr. Reddy’s today announced the final approval of its olanzapine 20 mg tablets, the generic version of Eli Lilly’s Zyprexa® from the USFDA.

All figures in millions, except EPS		All US dollar figures based on convenience translation rate of 1USD = 49.05

Dr. Reddy’s Laboratories Limited and Subsidiaries
Unaudited Consolidated Income Statement

		Q2 FY12												Q2 FY11												Growth
Particulars		($)				()				%				($)				()				%				%
Revenue			462				22,679				100				381				18,704				100				21
Cost of revenues			214				10,473				46				178				8,718				47				20
Gross profit			249				12,206				54				204				9,986				53				22
Operating Expenses
Selling, general & administrative expenses			147				7,216				32				116				5,709				31				26
Research and development expenses			30				1,459				6				26				1,270				7				15
Other operating (income) / expense			(4	)			(215	)			(1	)			(4	)			(218	)			(1	)			(2	)
Results from operating activities			76				3,745				17				66				3,225				17				16
Net finance (income) / expense			1				50				0				1				35				0				42
Share of (profit) / loss of equity accounted investees			(0	)			(13	)			(0	)			(0	)			(3	)			(0	)			—
Profit / (loss) before income tax			76				3,709				16				65				3,194				17				16
Income tax (benefit) / expense			13				631				3				7				327				2				93
Profit / (loss) for the period			63				3,078				14				58				2,867				15				7
Diluted EPS			0.4				18.1								0.3				16.9

Profit Reconciliation:

		Q2 FY12								Q2 FY11
Adjusted EBITDA Reconciliation		($)				()				($)				()
PBT			76				3,709				65				3,194
Interest			5				225				0				6
Depreciation			18				879				15				731
Amortization			8				389				6				317
Reported EBITDA			106				5,203				87				4,248
Adjustments:
Part reversal of provision booked in Q1 for Voluntary Retirement Scheme			(2	)			(94	)
Adjusted EBITDA			104				5,109				87				4,248

		Q2 FY12								Q2 FY11
Adjusted PAT Reconciliation		($)				()				($)				()
Reported PAT			63				3,078				58				2,867
Adjustments:
Interest on Bonus Debentures			2				118
Part reversal of provision booked in Q1 for Voluntary Retirement Scheme			(2	)			(94	)
Tax normalizing adjustment			(0	)			(4	)
Adjusted PAT			63				3,099				58				2,867

Segmental Analysis

Global Generics

Revenues from Global Generics segment are at 16.1 billion ($329 million) in Q2 FY12 registering growth of 18% over previous year.

•

Revenues from North America at 6.3 billion in Q2 FY12 versus 4.4 billion in Q2 FY11. Growth in USD terms of 45% was led by new product launches in the last twelve months and market share improvement in key products.

•

5 new products launched during the quarter, including limited competition products such as fondaparinux and fexofenadine pseudoephedrine D24 OTC.

•

24 products of our prescription portfolio feature among the Top 3 rank in market share (Source: IMS Sales Volumes July 2011).

•

During the quarter, 4 ANDAs were filed. The cumulative ANDA filings as of 30th September, 2011 are 177. A total of 76 ANDAs are pending for approval with the USFDA of which 40 are Para IVs and 11 are FTFs.

•

Revenues in Russia & Other CIS markets at 3.4 billion in Q2 FY12 versus 2.8 billion in Q2 FY11, year-on-year growth of 23%.

•

Revenues in Russia at 2.9 billion in Q2 FY12 versus 2.3 billion in Q2 FY11, year-on-year growth in USD terms of 30%, largely driven by volume growth in key brands.

•

OTC portfolio growth of 33% over previous year; OTC sales at 25% of overall Russia sales.

•

Dr. Reddy’s year-on-year secondary prescription sales growth at 20% versus industry’s growth of 10%. (Source: Pharmexpert August 2011). Dr. Reddy’s is ranked 12th in market share.

•

Revenues in Other CIS markets remained flat at 477 million in Q2 FY12.

•

Revenues in India increased by 9% to 3.5 billion in Q2 FY12 versus 3.2 billion in Q2 FY11.

•

3 new products launched during the quarter.

•

Biosimilar portfolio growth of 22% over previous year ; represents 6% to sales.

•

Revenues from Europe at 2.1 billion in Q2 FY12, declined by 10% over previous year.

•

Revenues from Germany declined by 27% to 1.2 billion in Q2 FY12 due to continuing impact of tenders.

•

Revenues from Rest of Europe grew by 26% to 933 million in Q2 FY12 driven by new launches in UK and growth in out-licensing business.

Pharmaceutical Services and Active Ingredients (PSAI)

Revenues from PSAI are at 5.9 billion in Q2 FY 12 versus 4.6 billion in Q2 FY11, year-on-year increase of 28%.

•

Growth in Active Ingredients business led by new product launches in Europe.

•

Pharmaceutical Services business grew on account of improved customer order book status.

•

During the quarter, 11 DMFs were filed globally, with 2 in US, 2 in Europe, 1 in Canada and 6 in rest of the markets. The cumulative DMF filings as of 30th September 2011 are 506.

Income Statement Highlights:

•

Gross profit at 12.2 billion ($249 million) in Q2 FY12, margin of 54% to revenues, marginal increase over previous year.

•

Selling, General & Administration (SG&A) expenses including amortization at 7.2 billion ($147 million) increased by 26% over Q2 FY11. This increase is on account of a) higher freight costs both on account of increase in sales volumes as well as rate increases, b) inflation and year-on-year increments linked increase in manpower costs across businesses, c) incremental costs at Bristol and Shreveport manufacturing facilities in the US and d) the increase in the OTC-related selling and marketing costs in Russia and other CIS markets as compared to previous year.

•

R&D expenses at 1.5 billion ($30 million) in Q2 FY12, increase of 15% over Q2 FY11.

•

Net Finance costs are at 50 million ($1 million) in Q2 FY 12 versus 35 million ($0.7 million) in Q2 FY11 The change is on account of :

•

Net forex gain of 151 million ($3 million) versus net forex loss of 49 million ($1 million) in Q2 FY11.

•

Net interest expense of 225 million ($5 million) in Q2 FY12 versus 5 million ($0.1 million) in Q2 FY11.

•

Profit on sale of investments of 25 million ($0.5 million) in Q2 FY12 versus 19 million ($0.4 million) in Q2 FY11.

	•		Adjusted EBITDA of 5.1 billion ($104 million) in Q2 FY12, is at 23% of revenues with year-on-year growth of 20%.
	•		Adjusted Profit after Tax for Q2 FY12 is at 3.1 billion ($63 million), is at 14% of revenues with year-on-year growth of 8%.
	•		Adjusted EPS for Q2 FY 12 is at 18.2 ($0.4) versus 16.9 ($0.3) in Q2 FY11.
	•		Capital expenditure for H1 FY12 is at 3.6 billion ($73 million).

Appendix 1: Key Balance Sheet Items		(in millions)

		As on 30th Sep 11								As on 30th Jun 11
Particulars		($)				()				($)				()
Cash and cash equivalents			155				7,596				111				5,468
Trade receivables			419				20,568				349				17,136
Inventories			379				18,592				355				17,401
Property, plant and equipment			641				31,450				622				30,524
Goodwill and Other Intangible assets			308				15,115				304				14,921
Loans and borrowings (current & non-current)			638				31,303				488				23,940
Trade payables			182				8,940				172				8,433
Equity			980				48,081				997				48,902

Appendix 2: Q2 FY12 Revenue Mix by Segment		(in millions)

		Q2 FY12												Q2 FY11
		($)				()				%				($)				()				%				Growth %
Global Generics			329				16,136				71				279				13,667				73				18
North America							6,287				39								4,416				32				42
Europe							2,117				13								2,366				17				(10	)
India							3,459				21								3,160				23				9
Russia & Other CIS							3,380				21								2,751				20				23
RoW							893				6								974				7				(8	)
PSAI			121				5,933				26				94				4,617				25				28
North America							1,068				18								814				18				31
Europe							2,303				39								1,551				34				48
India							752				13								653				14				15
RoW							1,810				31								1,599				35				13
Others			12				610				3				9				420				2				45
Total			462				22,678				100				381				18,704				100				21

Appendix 3: Q2 FY12 Revenue Mix by Geography		(in millions)

		Q2 FY12												Q2 FY11												Growth
		($)				()				%				($)				()				%				%
North America			159				7,777				34				111				5,464				29				42
Europe			92				4,536				20				84				4,102				22				11
India			86				4,210				19				78				3,813				20				10
Russia & Other CIS			69				3,380				15				56				2,751				15				23
Others			57				2,775				12				52				2,573				14				8
Total			462				22,678				100				381				18,704				100				21

Appendix 4: H1 FY12 Consolidated Income Statement

All figures in millions, except EPS		All US dollar figures based on convenience translation rate of 1USD = 49.05

		H1 FY12												H1 FY11												Growth
Particulars		($)				()				%				($)				()				%				%
Revenue			866				42,462				100				724				35,535				100				19
Cost of revenues			402				19,701				46				339				16,635				47				18
Gross profit			464				22,761				54				385				18,900				53				20
Operating Expenses
Selling, general & administrative expenses			285				13,972				33				228				11,191				31				25
Research and development expenses			54				2,656				6				46				2,263				6				17
Other operating (income) / expense			(8	)			(401	)			(1	)			(8	)			(404	)			(1	)			(1	)
Results from operating activities			133				6,533				15				119				5,850				16				12
Net finance (income) / expense			2				96				0				4				212				1				(55	)
Share of (profit) / loss of equity accounted investees			(0	)			(17	)			(0	)			(0	)			(8	)			(0	)			113
Profit / (loss) before income tax			132				6,455				15				115				5,647				16				14
Income tax (benefit) / expense			15				751				2				14				684				2				10
Profit / (loss) for the period			116				5,704				13				101				4,963				14				15
Diluted EPS			0.7				33.6								0.6				29.2

Appendix 5: H1 FY12 Profit Reconciliation		(in millions)

		H1 FY12								H1 FY11
Adjusted EBITDA Reconciliation		($)				()				($)				()
PBT			132				6,455				115				5,647
Interest			9				446				(0	)			(3	)
Depreciation			35				1,708				29				1,416
Amortization			16				794				12				605
Reported EBITDA			192				9,404				156				7,665
Adjustments:
One-time charge of Voluntary Retirement Scheme			1				42
Adjusted EBITDA			193				9,445				156				7,665

		H1 FY12								H1 FY11
Adjusted PAT Reconciliation		($)				()				($)				()
Reported PAT			116				5,704				101				4,963
Adjustments:
Interest on Bonus Debentures			5				236
One-time charge of Voluntary Retirement Scheme			1				42
Tax normalizing adjustment			(7	)			(364	)
Adjusted PAT			115				5,618				101				4,963

About Dr. Reddy’s

Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three business segments — Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products — Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Focus markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, Australia and New Zealand. For more information, log on to: www.drreddys.com

Disclaimer

This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

CONTACT INFORMATION

Investors and Financial Analysts:

Kedar Upadhye at kedaru@drreddys.com or on +91-40-66834297
Raghavender R at raghavenderr@drreddys.com or on +91-40-49002135
Milan Kalawadia (North America) at mkalawadia@drreddys.com or on +1-9082034931

Media:

Rajan S at rajans@drreddys.com or on +91-40- 49002445

Note: All discussions in this release are based on unaudited consolidated IFRS financials.

Press Release
		Dr. Reddy’s Laboratories Ltd.
		8-2-337, Road No. 3
		Banjara Hills, Hyderabad — 500 034
		Andhra Pradesh, India
		Tel: 91-40-4900-2900
		Fax: 91-40-4900-2999
		www.drreddys.com

Teva and Dr. Reddy’s announce launch of generic Zyprexa^® in the United States

Hyderabad, India, October 25, 2011:

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and Dr. Reddy’s Laboratories (NYSE: RDY) announced today the commercial launch of Olanzapine Tablets, the generic version of Eli Lilly’s Zyprexa^®. Annual sales of Zyprexa^® were approximately $3.2 billion in the United States as of September 2011, based on IMS sales data.

Teva’s Olanzapine Tablets in 2.5 mg, 5 mg, 7.5 mg, 10 mg and 15 mg and Dr. Reddy’s Olanzapine Tablets in 20 mg have each been awarded a 180-day period of marketing exclusivity in the U.S. Dr. Reddy’s is supplying the 20 mg version of the product following an April 2011 commercialization, manufacture and supply agreement with Teva. In addition, as per the terms of the agreement, Dr. Reddy’s will launch their 2.5 mg, 5 mg, 7.5 mg, 10 mg ,15 mg and 20 mg of Olanzapine tablets upon expiration of the 180-day exclusivity period.

ZYPREXA^® is a trademark of Eli Lilly and Company

Disclaimer

This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Dr. Reddy’s

Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products — Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetes, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand. For more information, log on to: www.drreddys.com

About TEVA

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world’s largest generic drug maker, with a global product portfolio of more than 1,300 molecules and a direct presence in about 60 countries. Teva’s branded businesses focus on CNS, oncology, pain, respiratory and women’s health therapeutic areas as well as biologics. Teva currently employs approximately 45,000 people around the world and reached $16.1 billion in net sales in 2010.

For more information please contact:

Investors and Financial Analysts:

Kedar Upadhye at kedaru@drreddys.com / +91-40-66834297
Raghavender R at raghavenderr@drreddys.com / +91-40-49002135
Milan Kalawadia (North America) at mkalawadia@drreddys.com / +1-908-203-4931

Media:

Rajan S at rajans@drreddys.com / +91-40-49002445

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.